Xeris Biopharma (XERS) Q2 FY26 earnings call

Xeris Biopharma delivered a record-breaking second quarter, driven by strong commercial momentum across its product portfolio, particularly Recorlev. The company strengthened its intellectual property and balance sheet, leading to a raised full-year revenue guidance. The pipeline asset XP-8121 is progressing towards Phase 3 initiation, with a detailed program overview planned for September.